Patent intelligence · US
US 7452887
Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
Patent details — US 7452887
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 18, 2008
- Expiration
- Nov 13, 2028
- Applicant
- Amphora Discovery Corporation
- Claims
- 42
- CPC classes
- A61K, A61K31/4709, A61K31/4725, A61K31/496
Quick answer
US 7452887 (Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof) is held by Amphora Discovery Corporation. Status: granted. Granted Nov 18, 2008. Expires Nov 13, 2028 (2 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Amphora Discovery Corporation
- Grant date
- Expiration
- Claims
- 42
- CPC classes
- A61K, A61K31/4709, A61K31/4725, A61K31/496, A61P, A61P1/04
More from Amphora Discovery Corporation
Related pharmaceutical patents in our USPTO index.
-
US 12427173
Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-CTLA-4 and/or anti-PD-1 antibodies to treat solid tumor malignancies
granted -
US 12428415
Matriptase 2 inhibitors and uses thereof
granted -
US 12421236
Seven-membered heterocyclic derivative acting as KRAS G12C mutant protein inhibitor
granted -
US 12420085
Synergistic therapies for inter vertebral disc degeneration
granted -
US 12421231
Azaindole derivatives and their use as ERK kinase inhibitors
granted -
US 12403069
Adapter for use in a planetary mixer
granted -
US 12398179
Nanomolar peptides and derivatives to differentially modulate ephrin receptors
granted -
US 12396924
Adapter for use in a planetary mixer
granted
Related coverage
Frequently asked questions
What is US patent 7452887?
US 7452887 (Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof) is held by Amphora Discovery Corporation. Status: granted. Granted Nov 18, 2008. Expires Nov 13, 2028 (2 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7452887?
Amphora Discovery Corporation is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 706 pharmaceutical patents for this assignee.
When does US 7452887 expire?
Our index shows an expiration date of Nov 13, 2028 (2 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.